medwireNews: The activated factor XI (XIa) inhibitor asundexian, given at a daily dose of 50 mg, was associated with a higher incidence of stroke or systemic embolism than apixaban in high-risk patients with atrial fibrillation enrolled in a phase 3 trial.
04-09-2024 | Atrial Fibrillation | News